Format
Sort by

Send to:

Choose Destination

Results: 5

Cited In for PubMed (Select 606763)

1.

Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults.

Flynn PM, Nachman S, Muresan P, Fenton T, Spector SA, Cunningham CK, Pass R, Yogev R, Burchett S, Heckman B, Bloom A, Utech LJ, Anthony P, Petzold E, Levy W, Siberry GK, Ebiasah R, Miller J, Handelsman E, Weinberg A; IMPAACT P1088 Team.

J Infect Dis. 2012 Aug 1;206(3):421-30. doi: 10.1093/infdis/jis360. Epub 2012 May 21. Erratum in: J Infect Dis. 2012 Dec 15;206(12):1951.

2.

Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults.

Keitel WA, Dekker CL, Mink C, Campbell JD, Edwards KM, Patel SM, Ho DY, Talbot HK, Guo K, Noah DL, Hill H.

Vaccine. 2009 Nov 5;27(47):6642-8. doi: 10.1016/j.vaccine.2009.03.015. Epub 2009 Mar 25.

3.

In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responses.

Co MD, Orphin L, Cruz J, Pazoles P, Green KM, Potts J, Leporati AM, Babon JA, Evans JE, Ennis FA, Terajima M.

Vaccine. 2009 Jan 7;27(2):319-27. doi: 10.1016/j.vaccine.2008.09.092. Epub 2008 Oct 31.

4.

Vaccines and antiviral drugs in pandemic preparedness.

Monto AS.

Emerg Infect Dis. 2006 Jan;12(1):55-60.

5.

Comparative antigenicity and immunogenicity of A/USSR/77 influenza vaccines in normal and primed mice.

McLaren C, Grubbs GE, Staton E, Barthlow W, Quinnan G, Ennis FA.

Infect Immun. 1980 Apr;28(1):171-7.

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk